Status:

COMPLETED

Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

Lead Sponsor:

Pfizer

Conditions:

Essential Hypertension

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Eligibility Criteria

Inclusion

  • Subject has mild to moderate hypertension

Exclusion

  • History of secondary hypertension

Key Trial Info

Start Date :

September 1 2005

Trial Type :

INTERVENTIONAL

End Date :

July 1 2006

Estimated Enrollment :

410 Patients enrolled

Trial Details

Trial ID

NCT00139698

Start Date

September 1 2005

End Date

July 1 2006

Last Update

December 5 2018

Active Locations (32)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (32 locations)

1

Pfizer Investigational Site

Medellín, Antioquia, Colombia

2

Pfizer Investigational Site

Barranquilla, Atlántico, Colombia

3

Pfizer Investigational Site

Cartagena, Atlántico, Colombia

4

Pfizer Investigational Site

Bogota, Cundinamarca, Colombia